---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-279720"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:28:57.162355+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics Q3 net loss $13.4M; cash $116.6M, runway to Q1 2025

## Summary
- Net loss of $13.4M ($0.44/share) vs $9.7M in Q3 2021; R&D expense $9.2M, up from $6.4M.
- Cash and marketable securities $116.6M as of Sept 30, 2022; expected to fund operations into Q1 2025.
- Suspends ImmunoPhage platform development to focus on TMAb platform for conditionally active antibodies.
- On track to submit IND for SNS-101 (anti-VISTA) in H1 2023; preclinical data presented at SITC.

## SEC filing metadata
- accession: 0001193125-22-279720
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312522279720/0001193125-22-279720-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312522279720/d405639d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-279720
- JSON: https://secwatch.observer/filing/0001193125-22-279720.json
- Plain text: https://secwatch.observer/filing/0001193125-22-279720.txt

## Key facts
- Earnings Releases
  Sensei Biotherapeutics, Inc. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312522279720/0001193125-22-279720-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.